TY - JOUR
T1 - Insulin-like growth factor-1, psoriasis, and inflammation
T2 - A ménage à trois?
AU - Savastano, S.
AU - Balato, N.
AU - Gaudiello, F.
AU - Di Somma, C.
AU - Brancato, V.
AU - Colao, A.
AU - Ayala, F.
AU - Tarantino, Giovanni
PY - 2011/9
Y1 - 2011/9
N2 - Psoriatic patients have an accumulation of metabolic syndrome (MS) and cardiovascular diseases (CVD), likely mediated by systemic inflammation, and exhibiting low circulating levels of insulin-like growth factor (IGF)-I, a marker of MS and CVD in the general population. The aim of this study is to determine the association of IGF-I and inflammation, and to assess the cardio-metabolic risk calculating the visceral adiposity index (VAI), in a group of psoriatic patients without MS. IGF-I, fibrinogen, C-reactive protein (CRP), and interleukin (IL)-6 levels were determined in 20 patients with moderate to severe psoriasis (age range 23-77 yrs) without MS, according to criteria of the National Cholesterol Education Program's Adult Panel III (ATP III), and 20 age- and BMI-matched controls. The standard deviation score (SDS) of IGF-I levels according to age (zSDS), the homeostasis model assessment of insulin resistance (HOMA-IR), the whole-body insulin sensitivity index (ISI), and VAI were also calculated. Psoriasis Area and Severity Index (PASI) mean value was 17.8±11. HDL cholesterol and IGF-I zSDS values were lower (p
AB - Psoriatic patients have an accumulation of metabolic syndrome (MS) and cardiovascular diseases (CVD), likely mediated by systemic inflammation, and exhibiting low circulating levels of insulin-like growth factor (IGF)-I, a marker of MS and CVD in the general population. The aim of this study is to determine the association of IGF-I and inflammation, and to assess the cardio-metabolic risk calculating the visceral adiposity index (VAI), in a group of psoriatic patients without MS. IGF-I, fibrinogen, C-reactive protein (CRP), and interleukin (IL)-6 levels were determined in 20 patients with moderate to severe psoriasis (age range 23-77 yrs) without MS, according to criteria of the National Cholesterol Education Program's Adult Panel III (ATP III), and 20 age- and BMI-matched controls. The standard deviation score (SDS) of IGF-I levels according to age (zSDS), the homeostasis model assessment of insulin resistance (HOMA-IR), the whole-body insulin sensitivity index (ISI), and VAI were also calculated. Psoriasis Area and Severity Index (PASI) mean value was 17.8±11. HDL cholesterol and IGF-I zSDS values were lower (p
KW - IGF-I
KW - Inflammation
KW - Metabolic syndrome
KW - Psoriasis
KW - Visceral adiposity index
UR - http://www.scopus.com/inward/record.url?scp=84858691206&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84858691206&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84858691206
VL - 9
SP - 277
EP - 283
JO - European Journal of Inflammation
JF - European Journal of Inflammation
SN - 1721-727X
IS - 3
ER -